Related Experiment Video

Updated: May 22, 2026

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression

Shu Feng1, Longjiang Shao, Wendong Yu

  • 1Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 11, 2012
PubMed
Abstract

Insights

Targeting fibroblast growth factor receptor (FGFR) signaling with AZ8010 effectively inhibits prostate cancer progression in vitro and in vivo. This approach shows promise for treating aggressive prostate cancer by reducing tumor growth, invasion, and angiogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Fibroblast growth factor receptor (FGFR) signaling is implicated in prostate cancer progression.
  • FGFRs play a critical role in tumor growth, invasion, and angiogenesis.

Purpose of the Study:

  • To evaluate the in vitro and in vivo efficacy of AZ8010, an FGFR inhibitor targeting all four FGFRs.
  • To determine if targeting FGFR signaling inhibits prostate cancer progression.

Main Methods:

  • AZ8010's effects on FGFR signaling and invasion were assessed in prostate epithelial and cancer cell lines.
  • In vitro invasion and proliferation assays were performed.
  • VCaP xenograft models were used to evaluate in vivo tumor progression.

Main Results:

  • AZ8010 inhibited FGFR-1 and FGFR-4 signaling, leading to reduced ERK phosphorylation and invasion in vitro.
  • In vivo, AZ8010 completely inhibited VCaP tumor growth, reduced angiogenesis and proliferation, and increased cell death.
  • Tumor growth inhibition was associated with decreased ERK phosphorylation.

Conclusions:

  • Targeting FGFR signaling with AZ8010 is a potent strategy against aggressive prostate cancer.
  • FGFR inhibition demonstrates significant anti-tumor activity, supporting its therapeutic potential.

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...